Author name: Leonardo Arias

En la historia de la ciencia abundan los nombres que pasaron a la inmortalidad: Newton, Galileo, Einstein… Pero hay otros, igual de brillantes, que permanecen en una relativa sombra. Uno de ellos es John Michell (1724–1793), un clérigo, geólogo y astrónomo brit&aacu …

Durante décadas, el ADN ha sido sinónimo de biología, medicina y genética. Lo asociamos con enfermedades hereditarias, evolución, medicina personalizada o pruebas de paternidad. Sin embargo, en los últimos años, esta famosa molécula ha empezado …

Durante siglos, religión y ciencia han sido presentadas como enemigos irreconciliables. Desde el juicio a Galileo hasta los debates actuales sobre evolución o bioética, el conflicto parece evidente. Pero ¿es realmente cierto que la religión solo ha sido un obst&aac …

In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal parts. Here are some of this year’s most glorious clinical trial victories.

As clinical research evolves, disruptive trial designs are reshaping how oncology advances. By integrating novel methodologies, strategic innovation, and patient-centered approaches, MEDSIR is driving a new era in cancer research, one that accelerates development, enhances efficiency, and delivers more meaningful therapeutic progress for patients worldwide.

Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting neurological diseases. Some failures split up partners, and one particularly egregious case even led to the demise of an entire company.

Coming up in the back half of December, the FDA will issue a verdict on Vanda Pharmaceuticals’ gastroparesis drug tradipitant, which it rejected last September, triggering a very public dispute with the company.

With notable therapies from Biogen, Sarepta and MacroGenics failing to show efficacy in pivotal or confirmatory trials, experts question the use of biomarker evidence for approval while one former regulator insists that a “failed trial is not a failed drug.”

Combining pulsed field ablation and a radiofrequency technique in one platform is expected to reduce procedure times.

The loss of domvanalimab is the latest in a string of high-profile failures recorded across the biopharma world for the TIGIT modality, including from GSK, Merck and Roche.